Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy

被引：0
|
作者：
Eissmann, Moritz [1 ]
Huber, Anne [1 ]
Allam, Amr [1 ]
Dijkstra, Christine [1 ]
Ernst, Matthias [1 ]
机构：
[1] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The maximum tumor growth rate predicts clinical outcomes of patients with small-cell lung cancer undergoing first-line chemotherapy plus immune-checkpoint inhibitor therapy
    Chen, Xiang
    Chen, Xueyuan
    Liu, Tingting
    Zhou, Ting
    Chen, Gang
    Zhou, Huaqiang
    Huang, Yan
    Fang, Wenfeng
    Yang, Yunpeng
    Zhou, Ningning
    Chen, Likun
    Mo, Silang
    Zhang, Li
    Zhao, Yuanyuan
    CANCER MEDICINE, 2023, 12 (07): : 8122 - 8133
  • [42] CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy
    Fengchang Yang
    Jiayi Zhang
    Liu Zhou
    Wei Xia
    Rui Zhang
    Haifeng Wei
    Jinxue Feng
    Xingyu Zhao
    Junming Jian
    Xin Gao
    Shuanghu Yuan
    European Radiology, 2022, 32 : 1538 - 1547
  • [43] CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy
    Yang, Fengchang
    Zhang, Jiayi
    Zhou, Liu
    Xia, Wei
    Zhang, Rui
    Wei, Haifeng
    Feng, Jinxue
    Zhao, Xingyu
    Jian, Junming
    Gao, Xin
    Yuan, Shuanghu
    EUROPEAN RADIOLOGY, 2022, 32 (03) : 1538 - 1547
  • [44] Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
    Ricciuti, Biagio
    Jones, Greg
    Severgnini, Mariano
    Alessi, Joao, V
    Recondo, Gonzalo
    Lawrence, Marissa
    Forshew, Tim
    Lydon, Christine
    Nishino, Mizuki
    Cheng, Michael
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [45] Exosomes Isolated from Ascites of T-cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response
    Menay, Florencia
    Herschlik, Leticia
    De Toro, Julieta
    Cocozza, Federico
    Tsacalian, Rodrigo
    Jose Gravisaco, Maria
    Paula Di Sciullo, Maria
    Vendrell, Alejandrina
    Waldner, Claudia I.
    Mongini, Claudia
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [46] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Cardin, Dana Backlund
    Spallanzani, Andrea
    Dragovich, Tomislav
    Shah, Usman
    Atasoy, Ajlan
    Ledeine, Jean-Marie
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, Luisa M.
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Luppi, Gabriele
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    Yang Jing
    Memaj, Arteid
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
    Kawakami, Hisato
    Hironaka, Shuichi
    Esaki, Taito
    Chayama, Kazuaki
    Tsuda, Masahiro
    Sugimoto, Naotoshi
    Kadowaki, Shigenori
    Makiyama, Akitaka
    Machida, Nozomu
    Hirano, Hidekazu
    Hirata, Kenro
    Hara, Hiroki
    Yabusaki, Hiroshi
    Komatsu, Yoshito
    Muro, Kei
    CANCERS, 2021, 13 (04) : 1 - 12
  • [49] Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort
    Naing, A.
    Khaki, A. R.
    Kummar, S.
    Al-Hallak, M. N.
    Razak, A. R. Abdul
    Diep, A. N.
    Schmidt, M.
    Maslyar, D.
    Vold, R.
    Hwang, C. C.
    Glatt, D. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S496 - S497
  • [50] IFN-γ-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy
    Pertl, U
    Luster, AD
    Varki, NM
    Homann, D
    Gaedicke, G
    Reisfeld, RA
    Lode, HN
    JOURNAL OF IMMUNOLOGY, 2001, 166 (11): : 6944 - 6951
12345